¿¬¼ö°­ÁÂ
(¿Â¶óÀÎ) 2020 Á¦ 16Â÷ ´ëÇѹé½ÅÇÐȸ ÃᡤÃß°èÇмú´ëȸ : 2020-09-18
(¿Â¶óÀÎ) 2020 Á¦ 16Â÷ ´ëÇѹé½ÅÇÐȸ ÃᡤÃß°èÇмú´ëȸ : 2020-09-18
±³À°ÀÏÀÚ : 2020-09-18
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 Á¦ 16Â÷ ´ëÇѹé½ÅÇÐȸ ÃᡤÃß°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ
´ã´çÀÚ : ÃÖ¼ö¿¬ 
¿¬¶ôó : 02-740-8364  
À̸ÞÀÏ : office@korvac.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ,      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í ¢º ȸ¿ø 1)Àü¹®ÀÇ,¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ¿¬±¸ÀÚ: »çÀüµî·Ï 5¸¸¿ø/»çÀüµî·ÏÀÌÈĵî·Ï 7¸¸¿ø 2) Àü°øÀÇ, ´ëÇлý, ´ëÇпø»ý ¹× ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø: »çÀüµî·Ï 3¸¸¿ø/»çÀüµî·ÏÀÌÈĵî·Ï 5¸¸¿ø ¢º ºñȸ¿ø: »çÀüµî·Ï 8¸¸¿ø/»çÀüµî·ÏÀÌÈĵî·Ï 10¸¸¿ø ¢º ÇöÀåµî·Ï ºÒ°¡      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09¿ù 18ÀÏ ¿Â¶óÀΠ09:00~09:00 Opening  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ09:00~09:25 Humoral immune response against COVID-19:long-term immunity and antibody dependent immune enhancement  ¹Ú¿Ï¹ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ09:25~09:50 Innate and T-cell immune response: perspectives on COVID-19 severity  ½ÅÀÇö(Ä«À̽ºÆ®) 
Åä·Ð 09¿ù 18ÀÏ ¿Â¶óÀΠ09:50~10:00 Q&A  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ10:00~10:25 µ¿¹°¿¡¼­ SARS-CoV-2 °Ë»ç¿Í Æò°¡  À¯±¤¼ö(ÀüºÏ´ë Àμö°øÅëÀü¿°º´¿¬±¸¼Ò) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ10:25~10:50 Animal models for COVID-19 vaccine  ÃÖ¿µ±â(ÃæºÏ´ë) 
Åä·Ð 09¿ù 18ÀÏ ¿Â¶óÀΠ10:50~11:00 Q&A  () 
È޽Ġ09¿ù 18ÀÏ ¿Â¶óÀΠ11:00~11:10 Coffee break  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ11:10~11:40 Global COVID-19 vaccine roadmap  Áö¿µ¹Ì(¼­¿ï´ë) 
±âŸ 09¿ù 18ÀÏ ¿Â¶óÀΠ11:40~12:00 ´ëÇѹé½ÅÇÐȸ ÆòÀÇ¿øȸ/ÃÑȸ  () 
½Ä»ç 09¿ù 18ÀÏ ¿Â¶óÀΠ12:00~13:00 e-Poster round & Lunch  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ13:00~13:25 DNA/mRNA-based COVID-19 vaccine  ¹Ú¼öÇü(Ä«À̽ºÆ®) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ13:25~13:50 Adenovirus-vectored COVID-19 vaccine  °­Ã¢À²(¼­¿ï´ë) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ13:50~14:15 Recombinant subunit COVID-19 vaccine  ±èÈÆ(SK bioscience) 
Åä·Ð 09¿ù 18ÀÏ ¿Â¶óÀΠ14:15~14:25 Q&A  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ14:25~14:55 Immune responses in children with COVID-19  ±è¿¹Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ14:55~15:15 Multi-system inflammatory syndrome and COVID-19  Á¶Àº¿µ(Ãæ³²ÀÇ´ë) 
È޽Ġ09¿ù 18ÀÏ ¿Â¶óÀΠ15:15~15:25 Coffee break  () 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ15:25~15:50 Evaluation criteria and rapid approval plan for COVID-19 vaccine clinical trials  ±èµµ±Ù(KFDA) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ15:50~16:15 ModelingÀ» ÅëÇÑ ¹é½Å È¿°ú ¿¹Ãø  Á¤Àº¿Á(°Ç±¹´ë) 
±³À°½Ã°£ 09¿ù 18ÀÏ ¿Â¶óÀΠ16:15~16:40 Consideration of priority for COVID-19 vaccination  Á¤ÈñÁø(°í·ÁÀÇ´ë) 
Åä·Ð 09¿ù 18ÀÏ ¿Â¶óÀΠ16:40~17:00 Panel discussion – KFDA, KCDC  () 
±âŸ 09¿ù 18ÀÏ ¿Â¶óÀΠ17:00~17:00 Closing  () 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,657 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,712 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,708 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼¼ºê¶õ½ºº´¿ø 2018 ¼¼¸ñȸ Çмú´ëȸ : 2018-11-10

±³À°ÀÏÀÚ : 2018-11-10 ±³À°Àå¼Ò : °­³² ¼¼ºê¶õ½ºº´¿ø ´ë°­´ç ±³À°ÁÖÁ¦ : 2018 ¼¼¸ñȸ Çмú´ëȸ ÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø ½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú ´ã´çÀÚ : ¹Ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,392 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,398 , ´ñ±Û¼ö : 0